Ribociclib (Kisqali) Pregnancy Risk Category: N Once the strong inhibitor is discontinued, (after at least 5 inhibitor half-lives of the strong CYP3A4 inhibitor have elapsed) the ribociclib dose is to be increased to the dose used prior to initiating the strong CYP3A inhibitor.Reduce the dose of ribociclib to 400mg once daily if coadministration with a strong CYP3A inhibitor cannot be avoided.Avoid coadministration with strong CYP3A inhibitors and consider alternatives with less potential for CYP3A inhibition.Dosage adjustment for concomitant strong CYP3A inhibitors:.If a ribociclib dose is missed or vomited, the next dose should be administered at the usual time and no additional dose should be given on the same day.A 28 days treatment cycle including a 600 mg orally once daily dose(in combination with fulvestrant or an aromatase inhibitor) for 21 days, followed by a 7-day period of rest continue until disease progression or unacceptable toxicity.Ribociclib (Kisqali) Dose in the treatment of advanced or metastatic Breast cancer: When giving ribociclib in combination with either an aromatase inhibitor or fulvestrant to pre/ perimenopausal women a luteinizing hormone-releasing hormone (LHRH) agonist should be administered to them.
In postmenopausal women, it is used in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in the management of HR-positive, HER2-negative advanced, or metastatic breast cancer.Ribociclib is used in pre/ peri or postmenopausal women as initial endocrine-based therapy for the management of (HR)-hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (along with an aromatase inhibitor).Ribociclib (Kisqali) is a cyclin D1/CDK4 and CDK6 inhibitor that is used to treat advanced and/ or metastatic breast cancer. Vaccines & immunoglobulins Vitamins Gout treatment Featured Video Consultation
0 kommentar(er)
